Summary {#sec0}
=======

Dynamic changes both in clinical profile and treatment strategy of non ST-segment elevation myocardial infarction (NSTEMI) patients have been observed recently. The exact impact of them on prognosis in a wide national population remains unclear. NSTEMI patients from the Polish Registry of Acute Coronary Syndromes (PL-ACS) were included to the analysis. In-hospital mortality decreased by fifty percent (in women from 6.6% to 3.3%; *p* \< 0.001 and in men from 4.9% to 2.5%; *p* \< 0.001, respectively). Similarly, 12-month mortality decreased up to one third (in women from 21.6% to 15.1%; *p* \< 0.001 and in men from 17.8% to 12.8%; *p* \< 0.001, respectively). Invasive strategy appeared to be the strongest factor decreasing mortality. Into in-hospital observation it reduces triple mortality risk whereas in 12-month follow up twice. Using propensity score matching analysis the impact of the treatment improvements on relative risk reduction was estimated on over 60%.

Introduction {#sec1}
============

In the last decade a non-ST-segment elevation myocardial infarction (NSTEMI) has become the most common MI type in Poland which is consistent with previous observations from the majority of Western European countries \[[@cit0001]\]. Simultaneously, dynamic changes in the clinical profile and the treatment strategy have been noticed, however their contribution to outcomes in a wide national population remains unclear \[[@cit0002]--[@cit0005]\].

Aim {#sec2}
===

Using the data from the Polish Registry of Acute Coronary Syndromes (PL-ACS) we analyzed the trends in clinical characteristics, treatment strategy and outcomes in almost two hundred thousand NSTEMI cases registered between 2005 and 2014.

Material and methods {#sec3}
====================

The study population was drawn from 463 hospitals in Poland providing care for patients with MI. It consists of patients admitted with a diagnosis of NSTEMI according to the guidelines of European Society of Cardiology (ESC) \[[@cit0006]--[@cit0008]\]. The study covers last 10-year period from 2005 to 2014. Contribution to the study was voluntary, nevertheless it comprises a half of all estimated cases of NSTEMI in Poland in that time. The study complies with the Declaration of Helsinki and was approved by the PL-ACS Registry committee.

Data was collected from the PL-ACS Registry questionnaires that include variables on demographic factors (gender, age), risk factors (smoking, arterial hypertension, hypercholesterolemia, diabetes mellitus and obesity), previous coronary incidences and procedures (MI, percutaneous coronary intervention (PCI), coronary artery by-pass grafting (CABG)), clinical presentation on admission (Killip class, heart rate, systolic blood pressure), electrocardiographic abnormalities (left ventricular ejection fraction (EF) -- echocardiographic assessment on admission), coronary angiography (CA), coronary intervention details and in-hospital and post-discharge treatment. In-hospital complications (including bleeding, stroke and re-infarction (ST-elevation in at least two contiguous leads in association with ischemic symptoms)) as well as in-hospital mortality together with 12-month follow-up were evaluated. Propensity score matching (PSM) was used to compensate for the nonrandomized design of the study to control for imbalances in patients characteristics.

Statistical analysis {#sec3.1}
--------------------

Females and males were analyzed separately. To assess age impact on outcomes the analysis was conducted in consecutive decades of life. Changes over time were investigated as comparison between subgroup in marginal 3-year intervals (2005--2007 and 2012--2014).

Categorical data are presented as numbers and percentages while continuous data as arithmetic mean ± standard deviation (SD). Differences in categorical variables were tested by χ^2^ test with Pearson modification whereas in continuous variables with Student *t*-test. A two-sided *p*-value ≤ 0.05 was considered significant. A logistic regression was used to identify variables that independently contributed to mortality. Propensity scores were calculated using a multiple regression model that included all covariates presented in [Table I](#t0001){ref-type="table"}. Matching was performed using a nearest neighbor algorithm. In-hospital and 12-month mortality were evaluated of the studied groups as well as propensity score-matched subgroups were evaluated. Finally, the impact of the change in the treatment strategy changes was estimated by comparison the relative risk reduction (RRR) in the PSM groups with the RRR in the entire study group.

###### 

Baseline characteristics of NSTEMI patients after propensity score matching

  Parameter                                Women          Men                                                     
  ---------------------------------------- -------------- -------------- ---------- -------------- -------------- ----------
  Risk factors:                                                                                                   
   Hypertension                            13489 (77.8)   13541 (78.1)   0.501      18399 (70.6)   18565 (71.2)   0.109
   Diabetes                                6106 (35.2)    6094 (35.1)    0.893      6387 (24.5)    6497 (24.9)    0.264
   Hypercholesterolemia                    7472 (43.1)    7496 (43.2)    0.795      11080 (42.5)   11165 (42.8)   0.452
   Smoking                                 2015 (11.6)    2102 (12.1)    0.149      8098 (31.1)    7997 (30.7)    0.338
   Obesity                                 4310 (24.8)    4338 (25.0)    0.729      4242 (16.3)    4369 (16.8)    0.134
   Prior MI                                3247 (18.7)    3069 (17.7)    0.013      5954 (22.8)    5570 (22.1)    0.054
   Prior PCI                               731 (4.2)      876 (5.1)      \< 0.001   1666 (6.4)     1987 (7.6)     \< 0.001
   Prior CABG                              693 (4.0)      690 (4.0)      0.934      1634 (6.3)     1650 (6.3)     0.773
  Clinical characteristics on admission:                                                                          
   SBP \< 100 mm Hg                        651 (3.8)      652 (3.8)      0.448      892 (3.6)      904 (3.5)      0.406
   SBP 100--160 mm Hg                      12232 (74.4)   12863 (75.0)   0.234      19417 (79.1)   20505 (79.3)   0.566
   SBP \> 160 mm Hg                        3559 (21.6)    3645 (21.2)    0.366      4247 (17.3)    4455 (17.2)    0.834
   HR \> 100/min                           2162 (13.1)    2113 (12.3)    0.029      2747 (11.2)    2779 (10.8)    0.169
   Killip class 4                          377 (2.2)      344 (2.0)      0.298      564 (2.2)      519 (2.0)      0.251
   Killip class 3                          939 (5.4)      834 (4.9)      0.025      1083 (4.2)     1008 (3.9)     0.179
   Killip class 2                          2826 (16.3)    2602 (15.2)    0.007      3477 (13.3)    3305 (12.9)    0.106
   ECG: sinus rythm                        14209 (86.1)   14678 (85.8)   0.427      21751 (88.2)   22682 (88.1)   0.904
   ECG: atrial fibrilation                 1690 (10.2)    1659 (9.7)     0.097      1950 (7.9)     1963 (7.6)     0.195
   ECG: pacemaker                          207 (1.3)      213 (1.2)      0.940      295 (1.2)      285 (1.1)      0.352
   ECG: ST-segment depression              7704 (44.4)    7675 (44.2)    0.754      10542 (40.5)   10675 (41.0)   0.236
   ECG: T-wave inversion                   3409 (19.7)    3384 (19.5)    0.735      4877 (18.7)    4836 (18.6)    0.645
   ECG: other ST-T abnormal.               5120 (29.5)    5044 (29.1)    0.370      8557 (32.8)    8383 (32.2)    0.104
   ECG: normal                             1623 (9.4)     1285 (7.4)     \< 0.001   2790 (10.7)    2198 (8.4)     \< 0.001
   LVEF \> 50%                             4010 (44.0)    6077 (43.9)    0.968      5802 (39.1)    8262 (38.9)    0.749
   LVEF 35--50%                            4174 (45.8)    6385 (46.2)    0.550      7116 (47.9)    10168 (47.9)   0.940
   LVEF \< 35%                             939 (10.3)     1372 (9.9)     0.355      1923 (13.0)    2794 (13.2)    0.566
   Time pain to admission 0--2 h           1919 (13.1)    1890 (12.4)    0.071      3169 (14.3)    3205 (13.9)    0.190
   Time pain to admission 2--12 h          7038 (48.2)    7361 (48.4)    0.652      10594 (47.9)   11149 (48.3)   0.339
   Time pain to admission \> 12 h          5650 (38.7)    5944 (39.1)    0.438      8376 (37.8)    8728 (37.8)    0.964
   Time pain to admission \> 24 h          3705 (25.4)    3905 (25.7)    0.508      5585 (25.20    5764 (25.0)    0.531
   Prehospital cardiac arrest              190 (1.1)      164 (0.9)      0.173      365 (1.4)      335 (1.3)      0.269

CABG -- coronary artery by-pass graft, ECG -- electrocardiogram, HR -- heart rate, LVEF -- left ventricle ejection fraction, MI -- myocardial infarction, PCI -- percutaneous coronary intervention, SBP -- systolic blood pressure.

Results {#sec4}
=======

A total of 197,192 patients (including 77,550 women, 39.3%) hospitalized in Poland due to NSTEMI between 2005 and 2014 were enrolled. All patients from two marginal 3-year periods (i.e. 2005--2007 and 2012--2014) were incorporated to the final analysis ([Table II](#t0002){ref-type="table"}). Two matched cohorts of 17,346 women as well as two matched cohorts of 26,059 men were created as a result of the propensity score matching ([Table I](#t0001){ref-type="table"}).

###### 

Baseline characteristics of NSTEMI patients

  Parameter                                Women          Men                                                     
  ---------------------------------------- -------------- -------------- ---------- -------------- -------------- ----------
  Risk factors:                                                                                                   
   Hypertension                            17908 (77.2)   20568 (80.5)   \< 0.001   22792 (68.8)   31219 (75.9)   \< 0.001
   Diabetes                                8180 (35.3)    9623 (37.3)    \< 0.001   7865 (23.7)    11999 (29.2)   \< 0.001
   Hypercholesterolemia                    10182 (43.9)   11264 (44.1)   0.671      14446 (43.6)   18067 (43.9)   0.337
   Smoking                                 2403 (10.4)    3340 (13.1)    \< 0.001   10595 (32.0)   10989 (26.7)   \< 0.001
   Obesity                                 5879 (25.4)    6391 (25.0)    0.400      5143 (15.5)    7807 (19.0)    \< 0.001
   Prior MI                                5899 (25.4)    5681 (22.2)    \< 0.001   10097 (30.5)   10728 (26.1)   \< 0.001
   Prior PCI                               736 (3.2)      4301 (16.8)    \< 0.001   1680 (5.1)     8534 (20.8)    \< 0.001
   Prior CABG                              1321 (5.7)     1092 (4.3)     \< 0.001   2764 (8.3)     2755 (6.7)     \< 0.001
  Clinical characteristics on admission:                                                                          
   SBP \< 100 mm Hg                        1034 (4.7)     813 (3.4)      \< 0.001   1407 (4.5)     1201 (2.9)     \< 0.001
   SBP 100--160 mm Hg                      15744 (71.1)   19698 (77.8)   \< 0.001   24468 (77.8)   33140 (81.1)   \< 0.001
   SBP \> 160 mm Hg                        5367 (24.2)    4795 (18.9)    \< 0.001   5588 (17.8)    6505 (15.9)    \< 0.001
   HR \> 100/min                           3713 (16.7)    2501 (9.9)     \< 0.001   4402 (13.9)    3470 (8.5)     \< 0.001
   Killip class 4                          662 (2.9)      388 (1.5)      \< 0.001   919 (2.8)      659 (1.6)      \< 0.001
   Killip class 3                          1932 (8.3)     995 (4.0)      \< 0.001   2052 (6.2)     1231 (3.0)     \< 0.001
   Killip class 2                          4349 (18.8)    3265 (13.0)    \< 0.001   5109 (15.4)    4462 (11.0)    \< 0.001
   ECG: sinus rythm                        18667 (83.6)   22072 (87.6)   \< 0.001   27506 (86.9)   36102 (88.9)   \< 0.001
   ECG: atrial fibrilation                 2728 (12.2)    2062 (8.2)     \< 0.001   2764 (8.7)     2822 (6.9)     \< 0.001
   ECG: pacemaker                          292 (1.3)      293 (1.2)      0.145      419 (1.3)      472 (1.2)      0.051
   ECG: ST-segment depression              11124 (48.8)   10361 (40.6)   \< 0.001   14564 (43.9)   15200 (37.0)   \< 0.001
   ECG: T-wave inversion                   6778 (29.2)    3795 (14.9)    \< 0.001   8798 (26.5)    5559 (13.5)    \< 0.001
   ECG: other ST-T abnormal.               5957 (14.9)    7725 (30.0)    \< 0.001   9802 (21.1)    13542 (32.8)   \< 0.001
   ECG: normal                             1648 (7.1)     3703 (14.5)    \< 0.001   2817 (8.5)     6857 (16.7)    \< 0.001
   LVEF \> 50%                             5077 (42.0)    8890 (43.3)    0.019      7015 (37.3)    12851 (38.2)   0.043
   LVEF 35--50%                            5647 (46.7)    9662 (47.1)    0.505      9062 (48.2)    16331 (48.6)   0.437
   LVEF \< 35%                             1370 (11.3)    1973 (9.6)     \< 0.001   2706 (14.4)    4421 (13.2)    \< 0.001
   Time pain to admission 0--2 h           3322 (16.7)    2247 (10.1)    \< 0.001   4966 (17.5)    4097 (11.3)    \< 0.001
   Time pain to admission 2--12 h          9227 (46.7)    10882 (48.7)   \< 0.001   13123 (46.2)   17726 (49.0)   \< 0.001
   Time pain to admission \> 12 h          7227 (36.5)    9205 (41.2)    \< 0.001   10342 (36.4)   14374 (39.7)   \< 0.001
   Time pain to admission \> 24 h          4850 (24.5)    5818 (26.0)    \< 0.001   7115 (25.0)    9157 (25.3)    \< 0.001
   Prehospital cardiac arrest              360 (1.6)      204 (0.8)      \< 0.001   712 (2.1)      389 (0.9)      \< 0.001

CABG -- coronary artery by-pass graft, ECG -- electrocardiogram, HR -- heart rate, LVEF -- left ventricle ejection fraction, MI -- myocardial infarction, PCI -- percutaneous coronary intervention, SBP -- systolic blood pressure.

In the last decade the mean age of males increased from 65.8 ±11.8 to 66.7 ±11.3 years (*p* \< 0.001), whereas the mean age of females slightly decreased from 72.3 ±10.8 to 72.1 ±11.0 years (*p* = 0.018). The frequency of major coronary artery disease risk factors like diabetes, arterial hypertension, obesity (in men only), smoking (in women only) increased. In the later years of the study the rate of prior PCI increased significantly. Additionally, there were substantial differences in Killip class, blood pressure, heart rate, ECG and echocardiography ([Table II](#t0002){ref-type="table"}). Differences in the baseline clinical characteristics were equalized by the propensity score matching model ([Table I](#t0001){ref-type="table"}).

During the last decade the frequency of invasive procedures increased remarkably in general population (coronary angiography from 35.8% to 90.7%; *p* \< 0.05 and percutaneous coronary intervention from 25.7% to 63.6%; *p* \< 0.05) as well as in PSM subgroups ([Table III](#t0003){ref-type="table"}). In addition there were also modifications in medical treatment scheme. The usage of P2Y12 -- inhibitors (especially clopidogrel) raised substantially from 56% in 2005--2007 to 93%; *p* \< 0.05 in 2012--2014 ([Table III](#t0003){ref-type="table"}).

###### 

Management of NSTEMI patients (after propensity score matching)

  Parameter                                   Women          Men                                                     
  ------------------------------------------- -------------- -------------- ---------- -------------- -------------- ----------
  Treatment strategy:                                                                                                
   Hospitalisation on cardiology depart.      12000 (69.2)   15420 (88.9)   \< 0.001   19222 (73.8)   23982 (92.0)   \< 0.001
   Conservative treatment                     11787 (68.0)   2255 (13.0)    \< 0.001   15032 (57.7)   2315 (8.9)     \< 0.001
   Coronary angiography                       5542 (32.0)    15090 (87.0)   \< 0.001   10998 (42.3)   23744 (91.1)   \< 0.001
   Percutaneous coronary intervention         3838 (22.1)    10021 (57.8)   \< 0.001   8015 (30.8)    16861 (64.7)   \< 0.001
   Second PCI (non-IRA) during indx hosp.     612 (3.6)      2268 (13.1)    \< 0.001   1149 (4.4)     2849 (10.9)    \< 0.001
   PCI with stent implantation                3357 (87.5)    9083 (90.5)    \< 0.001   7719 (88.9)    15434 (91.3)   \< 0.001
   PCI with BMS implantation                  3192 (83.2)    4115 (41.0)    \< 0.001   6808 (85.0)    6618 (39.1)    \< 0.001
   PCI with DES implantation                  165 (4.3)      4968 (49.5)    \< 0.001   311 (3.9)      8816 (52.2)    \< 0.001
   Intra aortic ballon pump                   52 (0.3)       88 (0.5)       0.023      105 (0.4)      143 (0.5)      0.016
  Medical treatment during hospitalisation:                                                                          
   Acetlosalycic acid                         15974 (92.1)   14271 (82.3)   \< 0.001   24244 (93.0)   21671 (83.2)   \< 0.001
   P2Y12B inhibitor                           9041 (52.1)    16096 (92.8)   \< 0.001   15581 (59.8)   24281 (93.2)   \< 0.001
   Clopidogrel                                7019 (40.5)    16040 (92.5)   \< 0.001   12625 (48.4)   24243 (93.0)   \< 0.001
   GPIIb/IIIa inhibitor                       371 (2.1)      1318 (7.6)     \< 0.001   880 (3.4)      2619 (10.1)    \< 0.001
   Heparin                                    12949 (74.7)   8919 (51.5)    \< 0.001   18988 (72.9)   13152 (50.5)   \< 0.001
   Beta-adrenolytic                           13705 (79.0)   11607 (66.9)   \< 0.001   20499 (78.7)   17790 (68.3)   \< 0.001
   Calcium channel blocker                    1664 (9.8)     2228 (12.8)    \< 0.001   2032 (7.8)     2878 (11.0)    \< 0.001
   Statin                                     13633 (78.6)   12311 (71.0)   \< 0.001   21050 (80.8)   19224 (73.8)   \< 0.001
   ACEI/ARB                                   13616 (78.8)   10529 (60.7)   \< 0.001   20166 (77.4)   16286 (62.6)   \< 0.001
   Nitrate                                    9366 (54.0)    2496 (14.4)    \< 0.001   13015 (49.9)   3448 (13.2)    \< 0.001
   Diuretics                                  6903 (39.8)    5100 (29.4)    \< 0.001   8082 (31.0)    6326 (24.3)    \< 0.001

ACEI/ARB -- angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, BMS -- bare metal stent, DES -- drug eluting stent, IRA -- infarct-related artery.

In that time the risk of in-hospital complications (re-infarction, stroke and cardiovascular death) decreased considerably. On the contrary, the risk of major bleeding incidences was higher in the later years of the study ([Table IV](#t0004){ref-type="table"}). In the whole population in-hospital mortality decreased by fifty percent (from 5.6% in 2005--2007 to 2.8% in 2012--2014; *p* \< 0.001, in women from 6.6% to 3.3%; *p* \< 0.001 and in men from 4.9% to 2.5%; *p* \< 0.001, respectively). Similarly, there was more than 30% decrease in the 12-month mortality (from 19.4% in 2005--2007 to 13.7% in 2012--2014; *p* \< 0.001, in women from 21.6% to 15.1%; *p* \< 0.001 and in men from 17.8% to 12.8%; *p* \< 0.001, respectively). Also in the PSM model the outcomes improved considerably -- in hospital mortality rates decreased by thirty percent whereas 12-month mortality decreased by 18% ([Table IV](#t0004){ref-type="table"}).

###### 

Outcomes of NSTEMI patients (after propensity score matching)

  Parameter                              Women         Men                                                  
  -------------------------------------- ------------- ------------- ---------- ------------- ------------- ----------
  Myocardial reinfarction                812 (4.7)     59 (0.3)      \< 0.001   1100 (4.3)    82 (0.3)      \< 0.001
  Stroke                                 101 (0.6)     54 (0.3)      \< 0.001   78 (0.3)      44 (0.2)      \< 0.001
  Bleeding                               145 (0.8)     270 (1.6)     \< 0.001   137 (0.5)     270 (1.0)     \< 0.001
  Cardiovascular mortality in hospital   964 (5.6)     630 (3.6)     \< 0.001   1051 (4.0)    717 (2.8)     \< 0.001
  Other cause of mortality in hospital   54 (0.3)      49 (0.3)      0.622      68 (0.3)      66 (0.3)      0.863
  In-hospital mortality                  1018 (5.9)    679 (3.9)     \< 0.001   1119 (4.3)    783 (3.0)     \< 0.001
  30-day mortality                       1535 (8.8)    1303 (7.5)    \< 0.001   1825 (7.0)    1534 (5.9)    \< 0.001
  6-month mortality                      2760 (15.9)   2204 (12.7)   \< 0.001   3322 (12.7)   2749 (10.6)   \< 0.001
  12-month mortality                     3474 (20.0)   2812 (16.2)   \< 0.001   4293 (16.5)   3544 (13.6)   \< 0.001

In the multivariable analysis the invasive strategy appeared to be the strongest factor decreasing mortality. It tripled the in-hospital and doubled the 12-month mortality rate reduction ([Table V](#t0005){ref-type="table"}).

###### 

Multivariate analysis of factors of in-hospital as well as 12-month mortality.

  Parameter                       In-hospital mortality   12-month mortality                       
  ------------------------------- ----------------------- -------------------- ------------------- -----------
  Gender -- female (vs. male)     1.02 (0.97--1.08)       0.4485               0.94 (0.92--0.97)   \< 0.0001
  Age (on each decade)            1.63 (1.59--1.68)       \< 0.0001            1.57 (1.55--1.59)   \< 0.0001
  Hypertension                    0.73 (0.69--0.78)       \< 0.0001            0.85 (0.83--0.88)   \< 0.0001
  Diabetes                        1.09 (1.03--1.15)       0.0021               1.29 (1.26--1.32)   \< 0.0001
  Hypercholesterolaemia            0.73 (0.69--0.77)      \< 0.0001            0.81 (0.79--0.83)   \< 0.0001
  Smoking                         1.02 (0.94--1.10)       0.6776               1.06 (1.03--1.10)   0.0005
  Obesity                         1.18 (1.10--1.26)       \< 0.0001            0.99 (0.96--1.02)   0.37
  Previuos MI                     1.07 (1.01--1.14)       0.0255               1.12 (1.09--1.15)   \< 0.0001
  Previous PCI                    0.80 (0.73--0.88)       \< 0.0001            0.90 (0.87--0.94)   \< 0.0001
  Previous CABG                   0.80 (0.71--0.91)       0.0006               0.84 (0.80--0.88)   \< 0.0001
  SBP \< 100 mm Hg                2.25 (2.08--2.45)       \< 0.0001            1.69 (1.62--1.77)   \< 0.0001
  SBP \> 160 mm Hg                0.48 (0.43--0.52)       \< 0.0001            0.68 (0.66--0.71)   \< 0.0001
  HR \> 100 /min                  1.31 (1.23--1.40)       \< 0.0001            1.23 (1.19--1.27)   \< 0.0001
  Killip 3 class                  3.67 (3.41--3.94)       \< 0.0001            1.98 (1.91--2.06)   \< 0.0001
  Killip 4 class                  13.2 (12.0--14.4)       \< 0.0001            4.48 (4.26--4.71)   \< 0.0001
  Other than sinus rythm on ECG   1.19 (1.12--1.27)       \< 0.0001            1.14 (1.11--1.18)   \< 0.0001
  ST-T abnormalities on ECG       1.16 (1.07--1.27)       0.0007               1.15 (1.11--1.19)   \< 0.0001
  LVEF 35--50%                    1.10 (1.01--1.20)       0.0240               1.52 (1.47--1.57)   \< 0.0001
  LVEF \< 35%                     2.31 (2.11--2.53)       \< 0.0001            2.67 (2.57--2.78)   \< 0.0001
  Time to admission \> 12 h       1.09 (1.03--1.16)       0.0030               1.03 (1.00--1.06)   0.022
  Prehospital cardiac arrest      2.37 (2.09--2.69)       \< 0.0001            1.74 (1.63--1.85)   \< 0.0001
  Invasive treatment              0.31 (0.29--0.33)       \< 0.0001            0.51 (0.49--0.52)   \< 0.0001

CABG -- coronary artery by-pass graft, ECG -- electrocardiogram, HR -- heart rate, LVEF -- left ventricle ejection fraction, MI -- myocardial infarction, PCI -- percutaneous coronary intervention, SBP -- systolic blood pressure.

An estimated impact of the treatment improvements on relative risk reduction in in-hospital mortality amounted to 67.8% in women and 61.6% in men, respectively. Similarly changes of the management in the last decade accounted for 63.3% (in women) and 62.6% (in men) of the relative risk reduction in 12-month mortality ([Figure 1](#f0001){ref-type="fig"}).

![Impact of the treatment improvements and clinical profile changes on mortality reduction in NSTEMI in 2005--2014](PWKI-16-40163-g001){#f0001}

Discussion {#sec5}
==========

The major finding of our study is the confirmation of the progress in therapeutic strategies to outcomes of the management of patients with NSTEMI in the last decade. The propensity score analysis revealed the substantial input (over 60%) of modern treatment into the overall benefit of prognosis. Irrespective of the clinical profile changes the routine invasive approach as well as modern medical therapies resulted in a spectacular mortality rates reduction.

As in many previous reports significant changes in the clinical characteristics, management and treatment outcomes of NSTEMI patients were observed \[[@cit0003]--[@cit0005]\]. The prevalence of major coronary risk factors like diabetes, obesity, arterial hypertension and chronic kidney disease is still increasing. On the contrary, percentage of smoking habit significantly decreased recently. Additionally, in the years 2005--2014 numerous changes in the clinical profile (mean age, gender, comorbidities and Killip class on admission) that might have impact on prognosis were noted \[[@cit0009]--[@cit0013]\].

Recently, a significant progress in the medical therapy was achieved, as the vast majority of NSTEMI patients receive double antiplatelet therapy (including P2Y12-receptor blockers). Previously, a significant proportion of patients were administered ticlopidine that was gradually substituted by clopidogrel and later by ticagrelor according to the guidelines of European Society of Cardiology \[[@cit0006]--[@cit0008]\]. Nevertheless, due to financial issue, the implantation of the novel antiplatelets agents in a routine practice was delayed in Poland compared with other countries.

An invasive approach became a predominant treatment strategy in NSTEMI \[[@cit0007], [@cit0008], [@cit0014], [@cit0015]\]. Importantly, the CA or PCI rates in Poland are currently equal to those in the Western Europe and United States \[[@cit0003], [@cit0004], [@cit0005], [@cit0016]\]. A rapid growth in invasive strategy utilization in Poland was distinctively noticeable in 2005--2011 that was mainly related to the opening of new catheterization laboratories. These allowed to follow ECS guidelines of that time on management of acute coronary syndromes in patients presenting without persistent ST-segment elevation from 2002 \[[@cit0006]\] and 2007 \[[@cit0007]\].

Multivariable analysis confirmed the significant invasive strategy contribution to outcomes which appear to be continuously better than previously reported \[[@cit0004], [@cit0009], [@cit0015]\].

In the last decade a spectacular decrease in mortality rates was observed in Poland which is in line with the reports from France, Sweden, Denmark and Germany \[[@cit0003], [@cit0005], [@cit0017], [@cit0018]\]. In contrast to the numerous other retrospective studies we applied the propensity score matching method to our analysis. By virtue of PSM the independent impact of the treatment development on outcomes was revealed. Interestingly, that input in prognosis improvements seems to be higher than it could be expected before.

Our study have several limitations. PL-ACS is a voluntary, observational study, and not all hospitals participated in the data collecting. Our analysis has a retrospective nature and some potentially important parameters might not be included. That is a single country study, therefore some trends should be interpreted with caution. Finally, propensity score matching analysis is based on a simplified model, even after data adjustment, the results could be biased by potentially important parameters that were not included.

Conclusions {#sec6}
===========

In Poland, the routine invasive strategy implementation contributed substantially to the outcomes of NSTEMI patients in the last 10 years. The impact of treatment advances on better prognosis was estimated at over sixty percent.
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